Gilead to file new CAR-T, setting up potential mid-2020 launchGilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing Share XGilead to file new CAR-T, setting up potential mid-2020 launchhttps://pharmaphorum.com/news/gilead-to-file-new-car-t/
Nearly half of lymphoma patients alive after Gilead’s CAR-T therapyNearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years, Share XNearly half of lymphoma patients alive after Gilead’s CAR-T therapyhttps://pharmaphorum.com/news/nearly-half-of-lymphoma-patients-alive-after-gileads-car-t-therapy/
Gilead’s Descovy approved in HIV prophylaxisThe FDA has approved Gilead’s combination drug Descovy for HIV prophylaxis in the US, offering a way of Share XGilead’s Descovy approved in HIV prophylaxishttps://pharmaphorum.com/news/gileads-descovy-approved-in-hiv-prophylaxis/
Building cell therapy leadership in EuropeIn these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind Share XBuilding cell therapy leadership in Europehttps://pharmaphorum.com/video/building-cell-therapy-leadership-europe/
Delivering innovative therapies with close industry-NHS partnershipsIt was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE) Share XDelivering innovative therapies with close industry-NHS partnershipshttps://pharmaphorum.com/r-d/views-analysis-r-d/delivering-innovative-therapies-with-close-industry-nhs-partnerships/
The top pharma companies by revenue 2018New analysis from GlobalData has revealed the top 20 pharma companies by revenue for 2018, with Johnson & Share XThe top pharma companies by revenue 2018https://pharmaphorum.com/views-and-analysis/the-top-pharma-companies-by-revenue-2018/
Gilead ups forecasts as new HIV drug boosts salesGilead has become the latest pharma company to raise its full year sales forecasts following stronger than expected Share XGilead ups forecasts as new HIV drug boosts saleshttps://pharmaphorum.com/news/gilead-ups-sales-forecasts-as-new-hiv-drug-boosts-sales/
Moving from autologous to allogeneic ACT paradigmsWe have come so far in a relatively short time with Adoptive Cellular Transfer (ACT). The two marketed Share XMoving from autologous to allogeneic ACT paradigmshttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/icon-allogeneic-adoptive-cellular-transfer/
Gilead’s R&D chief to step down as new CEO O’Day rings the changesGilead’s chief scientific officer, John McHutchison is to leave the company at the beginning of next month during Share XGilead’s R&D chief to step down as new CEO O’Day rings the changeshttps://pharmaphorum.com/news/gileads-rd-chief-to-step-down-as-new-ceo-oday-rings-the-changes/
